The trading price of Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) closed lower on Monday, March 03, and closing at $0.51, -5.43% lower than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $2.05 and a 52-week low of $0.51. Over the past month, the stock has lost -16.14% in value.
Adaptimmune Therapeutics Plc ADR, whose market valuation is $130.68 million at the time of this writing, is expected to release its quarterly earnings report in April. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.15 per share this quarter, however they have predicted annual earnings per share of -0.14 for current year and -0.47 for next year.
From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 183.73M.
On the technical side, indicators suggest ADAP has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned ADAP a recommendation rating is 6. Out of them, 1 rate it a Hold, while 4 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Adaptimmune Therapeutics Plc ADR (ADAP) as Underweight, while 1 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that ADAP’s price is currently -11.17% off the SMA20 and -13.05% off the SMA50. The RSI metric on the 14-day chart is currently showing 33.32, and weekly volatility stands at 11.88%. When measured over the past 30 days, the indicator reaches 7.44%. Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s beta value is currently sitting at 2.51, while the Average True Range indicator is currently displaying 0.05. With analysts defining $1-$4 as the low and high price targets, we arrive at a consensus price target of $3 for the trailing 12-month period. The current price is about -96.08% off the estimated low and -684.31% off the forecast high, based on this estimate. Investors will be thrilled if ADAP’s share price rises to $3, which is the median consensus price. At that level, ADAP’s share price would be -488.24% below current price.
To see how Adaptimmune Therapeutics Plc ADR stock has been performing in comparison to its peers in the industry, here are the numbers: ADAP stock’s performance was -5.43% in the latest trading, and -68.28% in the past year, while Sangamo Therapeutics Inc. (SGMO) has traded -9.75%% on the day and positioned -9.75% lower than it was a year ago. Another comparable company uniQure N.V. (QURE) saw its stock close -17.11%% lower in the most recent trading session but was up 111.24% in a year.
An evaluation of the daily trading volume of Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) indicates that the 3-month average is 1.63 million.
Currently, records show that 255.70 million of the company’s shares remain outstanding. The insiders hold 11.49% of outstanding shares, whereas institutions hold 37.29%. However, since the stock’s price has seen -5.20% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
